A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells

Antibody-drug conjugates (ADCs) have recently emerged as efficient and selective cancer treatment therapeutics. Currently, alternative forms of drug carriers that can replace monoclonal antibodies are under intensive investigation. Here, a cytotoxic conjugate of an anti-HER2 (Human Epidermal Growth...

Descripción completa

Detalles Bibliográficos
Autores principales: Serwotka-Suszczak, Anna M., Sochaj-Gregorczyk, Alicja M., Pieczykolan, Jerzy, Krowarsch, Daniel, Jelen, Filip, Otlewski, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343935/
https://www.ncbi.nlm.nih.gov/pubmed/28216573
http://dx.doi.org/10.3390/ijms18020401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343935/
https://www.ncbi.nlm.nih.gov/pubmed/28216573
http://dx.doi.org/10.3390/ijms18020401

Ejemplares similares